EVA Pharma, one of the fastest-growing pharmaceutical companies in the Middle East and Africa (MEA), has recently celebrated its ground-breaking ceremony for its state-of-the-art pharmaceutical research and manufacturing complex in Sudair, the first of its kind in the Kingdom, and the opening of its Riyadh office. Consulting and planning company io is responsible for the concept design of the complex with a vision for a greener and more sustainable future.
With a production capacity of about one billion units annually, this production facility aims to become a center of gravity for pharmaceutical manufacturing in the region with sustainable accessibility for innovative healthcare solutions. It will comprise an R&D center with a multitude of various types of dosage forms such as DPIs, Bi-layer tablets, and ODT. The complex will produce over 150 pharmaceutical products, spanning various therapeutic areas and addressing the most demanding health challenges in the Kingdom.
"On the personal level and as a representative of the 5000 people in EVA Pharma we feel very blessed to be here and we feel very excited about what we can bring to Saudi patients and to Arab patients in the next months and years. This assembly of manufacturing facilities will bring cutting-edge technologies to Saudi, so that the kingdom can reach the healthcare independence that it aspires to have,” said Riad Armanious, CEO of EVA Pharma.
EVA Pharma's strategic move into Saudi Arabia underscores its dedication to supplying unmet patient needs and marks its initial steps in the Saudi market through substantial local investments. By establishing a pharmaceutical research and manufacturing complex in Sudair, EVA Pharma aims to contribute to the Kingdom's Vision 2030 healthcare goals of increasing local pharmaceutical production. The health sector transformation program aims to raise the private sector's contribution to 50%, a substantial increase from the current 11%.
Focus on a green circular economy approach
The Sudair complex is designed by io. The consulting and planning company is responsible for the overall architectural design, master planning and block layout of production dosage forms (cosmetics, sterile and solid production) as well as central packaging and logistics, water treatment, process technology, administration, and all ancillary functions. With its strategic concept, a phased realization approach and 3D visualization, io has focused on an architectural language reflecting both the local culture and climate to develop a sustainable future-proof production site.
Contributing to the overall reduction of environmental impact, the complex will incorporate solar panels, on-site water recycling and waste treatment systems. The design of the complex not only pays homage to cultural roots but also strategically minimizes heat gain, thereby significantly reducing its carbon footprint. Temperatures fluctuate between sub-zero and plus 50 degrees. Tents and lightweight materials used for the sail provide shade and cooling via natural flow of air. The tent shape serves as passive energy providing shade for the building itself, especially on the warmest side. The sails are equipped with organic photovoltaics that together with the extensive rooftop photovoltaic panels will be designed to produce up to 3 megawatts solar energy.
Showcasing EVA Pharma’s environmentally conscious approach aligns seamlessly with Saudi Arabia's vision for a greener and more sustainable future.
About EVA Pharma for Industry
EVA Pharma for Industry is a subsidiary of EVA Pharma Holdings, one of the fastest-growing healthcare companies in the Middle East and Africa. EVA Pharma for Industry is registered in the Kingdom of Saudi Arabia as a local pharmaceutical manufacturer with a focus on sustainability and local investment in the Kingdom.
EVA Pharma empowers the fight for health and well-being in communities around the world. With a 5,000-strong team of professionals in 40+ countries, the company produces more than one million healthcare products a day at its state-of-the-art manufacturing facilities, which are equipped with cutting-edge technology, are internationally recognized for innovation, and have been approved by multiple regulatory agencies.
The company’s product portfolio focuses on pressing, yet unmet, disease areas, such as diabetes and cardiovascular diseases, oncology, neuroscience, ophthalmology, anti-infectives, bone and pain, hepatology, and reproductive health, to meet both local and international demand.
Media Contact:
Ahmed Helal | Head of Communications | ahmed.helal@evapharma.com | +20-1000254529
With a production capacity of about one billion units annually, this production facility aims to become a center of gravity for pharmaceutical manufacturing in the region with sustainable accessibility for innovative healthcare solutions. It will comprise an R&D center with a multitude of various types of dosage forms such as DPIs, Bi-layer tablets, and ODT. The complex will produce over 150 pharmaceutical products, spanning various therapeutic areas and addressing the most demanding health challenges in the Kingdom.
"On the personal level and as a representative of the 5000 people in EVA Pharma we feel very blessed to be here and we feel very excited about what we can bring to Saudi patients and to Arab patients in the next months and years. This assembly of manufacturing facilities will bring cutting-edge technologies to Saudi, so that the kingdom can reach the healthcare independence that it aspires to have,” said Riad Armanious, CEO of EVA Pharma.
EVA Pharma's strategic move into Saudi Arabia underscores its dedication to supplying unmet patient needs and marks its initial steps in the Saudi market through substantial local investments. By establishing a pharmaceutical research and manufacturing complex in Sudair, EVA Pharma aims to contribute to the Kingdom's Vision 2030 healthcare goals of increasing local pharmaceutical production. The health sector transformation program aims to raise the private sector's contribution to 50%, a substantial increase from the current 11%.
Focus on a green circular economy approach
The Sudair complex is designed by io. The consulting and planning company is responsible for the overall architectural design, master planning and block layout of production dosage forms (cosmetics, sterile and solid production) as well as central packaging and logistics, water treatment, process technology, administration, and all ancillary functions. With its strategic concept, a phased realization approach and 3D visualization, io has focused on an architectural language reflecting both the local culture and climate to develop a sustainable future-proof production site.
Contributing to the overall reduction of environmental impact, the complex will incorporate solar panels, on-site water recycling and waste treatment systems. The design of the complex not only pays homage to cultural roots but also strategically minimizes heat gain, thereby significantly reducing its carbon footprint. Temperatures fluctuate between sub-zero and plus 50 degrees. Tents and lightweight materials used for the sail provide shade and cooling via natural flow of air. The tent shape serves as passive energy providing shade for the building itself, especially on the warmest side. The sails are equipped with organic photovoltaics that together with the extensive rooftop photovoltaic panels will be designed to produce up to 3 megawatts solar energy.
Showcasing EVA Pharma’s environmentally conscious approach aligns seamlessly with Saudi Arabia's vision for a greener and more sustainable future.
About EVA Pharma for Industry
EVA Pharma for Industry is a subsidiary of EVA Pharma Holdings, one of the fastest-growing healthcare companies in the Middle East and Africa. EVA Pharma for Industry is registered in the Kingdom of Saudi Arabia as a local pharmaceutical manufacturer with a focus on sustainability and local investment in the Kingdom.
EVA Pharma empowers the fight for health and well-being in communities around the world. With a 5,000-strong team of professionals in 40+ countries, the company produces more than one million healthcare products a day at its state-of-the-art manufacturing facilities, which are equipped with cutting-edge technology, are internationally recognized for innovation, and have been approved by multiple regulatory agencies.
The company’s product portfolio focuses on pressing, yet unmet, disease areas, such as diabetes and cardiovascular diseases, oncology, neuroscience, ophthalmology, anti-infectives, bone and pain, hepatology, and reproductive health, to meet both local and international demand.
Media Contact:
Ahmed Helal | Head of Communications | ahmed.helal@evapharma.com | +20-1000254529
